Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription 05.10.2026 4 Ann Surg Oncol 3 Anticancer Res 3 BMC Cancer 1 Cancer 1 Cancer Lett 1 Cancer Res 2 Clin Cancer Res 1 Clin Lung Cancer 1 Eur J Cancer 1 Int J Cancer 1 J Cancer Res Clin Oncol 1 J Clin Invest 1 J Nucl Med 1 J Thorac Cardiovasc Surg 12 J Thorac Oncol 1 Lancet 1 Lancet Oncol 5 Lung Cancer 1 Nat Med 1 Oncogene 2 Oncol Rep 1 Oncologist 1 PLoS One 1 Science

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg Oncol

1. ZHANG L, Wang Y, Wang X, Li C, et al
   Impact of Neoadjuvant Immunotherapy Combined with Chemotherapy on Surgical Margin Strategy in Central Non-Small-Cell Lung Cancer.
   Ann Surg Oncol. 2026 Oct 2. doi: 10.1245/s10434-026-20572.
   PubMed         Abstract available
   
   
2. AO Y, Han Z, Xia M, Wen J, et al
   ASO Visual Abstract: A Novel Prognostic Stratification for Patients with Non-Small Cell Lung Cancer following Surgical Resection after Neoadjuvant Therapy: A Retrospective Cohort Study.
   Ann Surg Oncol. 2026 Oct 1. doi: 10.1245/s10434-026-20678.
   PubMed        
   
   
3. WATANABE T, Nomura K, Takamori S, Tane S, et al
   ASO Visual Abstract: Perioperative Outcomes and Pathological Response After Neoadjuvant Nivolumab Plus Platinum Chemotherapy in Clinically Node-Negative Non-Small Cell Lung Cancer.
   Ann Surg Oncol. 2026 Sep 30. doi: 10.1245/s10434-026-20633.
   PubMed        
   
   
4. AO Y, Han Z, Xia M, Wen J, et al
   A Novel Prognostic Stratification for Patients with Non-small Cell Lung Cancer Following Surgical Resection After Neoadjuvant Therapy: A Retrospective Cohort Study.
   Ann Surg Oncol. 2026 Sep 28. doi: 10.1245/s10434-026-20600.
   PubMed         Abstract available
   
   

   
   Anticancer Res

5. ISHIKAWA Y, Shigeta N, Nemoto D, Yasuura Y, et al
   Prior Extrapulmonary Malignancy and Outcomes After Lung Cancer Resection.
   Anticancer Res. 2026;46:5541-5551.
   PubMed         Abstract available
   
   
6. SHOJI F, Wakasu S, Kosai K, Kinoshita F, et al
   Baseline Gut Microbiota Composition Links Immune-nutritional Status to Clinical Outcomes in Non-small Cell Lung Cancer Treated With Atezolizumab-based Immunotherapy: A Multicenter Prospective Study.
   Anticancer Res. 2026;46:5565-5575.
   PubMed         Abstract available
   
   
7. TANIGUCHI Y, Tanaka T, Tamiya M, Tamiya A, et al
   Clinical Outcomes and Prognostic Factors of ABCP Therapy in EGFR-mutated NSCLC in the Osimertinib Era.
   Anticancer Res. 2026;46:5609-5617.
   PubMed         Abstract available
   
   

   
   BMC Cancer

8. JIAO R, Wu C, Zhang T, Yan H, et al
   Machine learning-driven development of a novel unfolded protein response-related gene signature for predicting lung adenocarcinoma patient prognosis.
   BMC Cancer. 2026;26:1173.
   PubMed         Abstract available
   
   
9. ZHANG Q, Xu Y, Liu J, Wang Y, et al
   LAR/NMLR stratify mortality risk before and after checkpoint inhibitor pneumonitis in NSCLC: multi-state and time-dependent analyses.
   BMC Cancer. 2026;26:1175.
   PubMed         Abstract available
   
   
10. YANG X, Huang G, Liu K, Wang D, et al
    Co-mutation landscape and prognostic impact of genomic complexity in EGFR-mutant non-small cell lung cancer.
    BMC Cancer. 2026;26:1158.
    PubMed         Abstract available
    
    

    
    Cancer

11. FLOREZ N, Patel SP, Salgia R, Sands J, et al
    Current challenges and emerging therapeutic strategies in lung cancer care: Insights from Bridging the Gaps 2025.
    Cancer. 2026;132:e70633.
    PubMed         Abstract available
    
    

    
    Cancer Lett

12. WANG Y, Qi F, Zhang M, Wang Q, et al
    The circulating tumor microenvironment in small-cell lung cancer: Vimentin-positive circulating tumor endothelial cells as drivers of metastasis and poor prognosis in a large cohort study.
    Cancer Lett. 2026;661:218852.
    PubMed         Abstract available
    
    

    
    Cancer Res

13. TARRAGO-CELADA J, Mahmood AS, Panina Y, Lalwani S, et al
    Targeting Cystine Addiction Suppresses Breast Cancer Lung Metastasis.
    Cancer Res. 2026 Jul 7. doi: 10.1158/0008-5472.CAN-25-3883.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

14. MA P, Zhou Y, Ma W, Wang Y, et al
    Intrathecal Allogeneic B7-H3-Targeted CAR gammadelta T Cells for Leptomeningeal Metastasis from Solid Tumors: Safety, Efficacy, and Immunologic Dynamics in a Phase I Trial.
    Clin Cancer Res. 2026;32:4341-4353.
    PubMed         Abstract available
    
    
15. SKOULIDIS F, Jabbour SK, Garon EB, Iyengar P, et al
    Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT).
    Clin Cancer Res. 2026;32:4461-4473.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

16. MIZUTANI M, Matsumoto Y, Ohe C, Sugimoto A, et al
    The Impact of Tumor Immune Microenvironment in EGFR-Mutant Non-Small Cell Lung Cancer on the Efficacy of Osimertinib.
    Clin Lung Cancer. 2026;27:1-10.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

17. YAMASHITA M, Ninomiya K, Tomida S, Nakata E, et al
    Molecular characteristics and clinical outcomes of ERBB2-activating mutation-positive non-small cell lung cancer: A Japanese nationwide real-world cohort.
    Eur J Cancer. 2026;248:117443.
    PubMed         Abstract available
    
    

    
    Int J Cancer

18. 
    Correction to "Comparisons of Blood, Upper Respiratory Tract and Gut Viromes From Patients With Lung Cancer and Healthy Persons".
    Int J Cancer. 2026 Sep 30. doi: 10.1002/ijc.70756.
    PubMed        
    
    

    
    J Cancer Res Clin Oncol

19. CHAHINE S, Diab T, El Tannir M, Farhat G, et al
    TFE3-rearranged PEComa with hepatic and pulmonary involvement: diagnostic challenges and resistance to mTOR-targeted therapy.
    J Cancer Res Clin Oncol. 2026;152:188.
    PubMed         Abstract available
    
    

    
    J Clin Invest

20. FIALKOFF G, Takahashi N, Sharkia I, Gutin J, et al
    Plasma nucleosome profiling reports on tumor burden and molecular subtypes in small cell lung cancer.
    J Clin Invest. 2026;136:e202151.
    PubMed         Abstract available
    
    

    
    J Nucl Med

21. CHOI H, Bae S, Na KJ
    End-to-End PET/CT Interpretation and Quantification with an LLM-Orchestrated AI Agent: A Real-World Pilot Study.
    J Nucl Med. 2026 Jun 18:jnumed.126.272362. doi: 10.2967/jnumed.126.272362.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

22. DAI ZY, Wei Y, Mi XQ, Xing YK, et al
    Oncological outcomes of left upper trisegmentectomy versus lobectomy for clinical stage I non-small cell lung cancer with occult lymph node metastasis: A target trial emulation with targeted minimum loss-based estimation and propensity score matching.
    J Thorac Cardiovasc Surg. 2026;172:820-831.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

23. CHOUDHURY NJ, Gezelius E, Arfe A, Baine M, et al
    Brief Report: Proposed Clinical Trial Guidelines Based on Clinicopathologic Heterogeneity of Metastatic Pulmonary Large Cell Neuroendocrine Carcinoma.
    J Thorac Oncol. 2026;21:104061.
    PubMed         Abstract available
    
    
24. BARBI J, Smith RJ Jr, Vedire YR, Washington D, et al
    Obesity Promotes Lung Carcinogenesis Through Airway Immune Dysfunction.
    J Thorac Oncol. 2026;21:104066.
    PubMed         Abstract available
    
    
25. ZHANG Z, Dong J, Huang Y, Liu Y, et al
    Gene-Specific Analysis of Clonal Hematopoiesis Identifies the Association between ASXL1 and Lung Cancer Risk.
    J Thorac Oncol. 2026 Sep 28:106124. doi: 10.1016/j.jtho.2026.106124.
    PubMed         Abstract available
    
    
26. LI MSC, Soon YY, Au-Yeung PY, Chan ALS, et al
    Efficacy and safety of HER2 directed therapies for advanced HER2-mutant non-small-cell lung cancer - a systematic review and meta-analysis.
    J Thorac Oncol. 2026 Sep 28:106129. doi: 10.1016/j.jtho.2026.106129.
    PubMed         Abstract available
    
    
27. PASQUINELLI MM, Durney CH, Hill T, Atueyi U, et al
    Brief Report: Validation of the Sybil Lung Cancer Risk Prediction Model in a Predominantly Black Screening Cohort.
    J Thorac Oncol. 2026 Sep 28:106128. doi: 10.1016/j.jtho.2026.106128.
    PubMed         Abstract available
    
    
28. AJONA D, Gomez-Ambrosi J
    Beyond BMI: Is Visceral Adiposity Reframing the Obesity Paradox in Lung Cancer?
    J Thorac Oncol. 2026;21:104119.
    PubMed        
    
    
29. TRAVIS WD, Baine MK, Beasley MB, Brambilla E, et al
    Advances in Pathology: Journal of Thoracic Oncology 20th Anniversary Series.
    J Thorac Oncol. 2026;21:104116.
    PubMed         Abstract available
    
    
30. HORNDALSVEEN H, Haakensen VD, Madebo T, Gronberg BH, et al
    ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab.
    J Thorac Oncol. 2026;21:103992.
    PubMed         Abstract available
    
    
31. BEASLEY MB, Yatabe Y, Papotti M, Cooper WA, et al
    IASLC Update on Classification of Pulmonary Neuroendocrine Neoplasms.
    J Thorac Oncol. 2026;21:103977.
    PubMed         Abstract available
    
    
32. XU X, Saad MB, Grippin A, Xu H, et al
    Brief Report: SARS-CoV-2 mRNA Vaccination Improved Survival in NSCLC Treated with Radiotherapy.
    J Thorac Oncol. 2026 Jun 1:103956. doi: 10.1016/j.jtho.2026.103956.
    PubMed         Abstract available
    
    
33. CHAUNZWA TL, Krishnan G, Book AJ, Miller DG, et al
    Thymic Composition Predicts Radiation Pneumonitis in Locally Advanced NSCLC.
    J Thorac Oncol. 2026;21:103949.
    PubMed         Abstract available
    
    
34. LIU X, Stamboulian M, Borgeaud M, Zhu E, et al
    Compound EGFR Mutations Are Predominantly P-Loop and Alpha-C Helix Compressing Mutations With Increased Responsiveness to Second- Versus Third-Generation Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2026;21:103948.
    PubMed         Abstract available
    
    

    
    Lancet

35. SIVA S, Yom SS
    Combining immunotherapy with stereotactic body radiation therapy in localised non-small-cell lung cancer.
    Lancet. 2026;408:1276-1277.
    PubMed        
    
    

    
    Lancet Oncol

36. GRUBER K
    Could Brazil's tuberculosis network detect lung cancer earlier?
    Lancet Oncol. 2026 Oct 1:S1470-2045(26)00527.
    PubMed        
    
    

    
    Lung Cancer

37. ELLIS SE, Shields PG, Myers JV, Reisinger SA, et al
    More than a risk factor: alcohol use following diagnosis in non-small cell lung cancer patients.
    Lung Cancer. 2026;221:109635.
    PubMed         Abstract available
    
    
38. DALLOUL Z, Abboud A, Dalloul I, Abdelsalam M, et al
    Real-world progression-free survival with erlotinib versus osimertinib in EGFR L858R + T790M compound mutation non-small cell lung Cancer: An exploratory analysis of the MSK-CHORD dataset.
    Lung Cancer. 2026;221:109637.
    PubMed         Abstract available
    
    
39. ZHOU S, Tan J, Patel V, Kishi N, et al
    Systemic and intracranial activity of antibody-drug conjugates in patients with non-small cell lung cancer and brain metastases: A systematic review and meta-analysis.
    Lung Cancer. 2026;221:109638.
    PubMed         Abstract available
    
    
40. ROST M, Wehr C, Mozaffari Jovein M, Kemper M, et al
    Lung cancer after allogeneic hematopoietic stem cell transplantation.
    Lung Cancer. 2026;221:109633.
    PubMed         Abstract available
    
    
41. MOSER D, Lang-Stoberl A, Fabikan H, Krainer-Jacobs J, et al
    Second-line therapy in extensive-stage small cell lung cancer: an unmet need highlighted by real-world evidence from the LALUCA registry.
    Lung Cancer. 2026;221:109639.
    PubMed         Abstract available
    
    

    
    Nat Med

42. O'LEARY K
    Biography of an inherited lung cancer risk gene.
    Nat Med. 2026 Sep 28. doi: 10.1038/d41591-026-00048.
    PubMed        
    
    

    
    Oncogene

43. FENG J, Zhao Q, Wang J, Li Z, et al
    KIFC1 engages RUNX2/TGF-beta signaling to promote lung cancer bone metastasis via disrupting bone homeostasis.
    Oncogene. 2026 Sep 25. doi: 10.1038/s41388-026-03998.
    PubMed         Abstract available
    
    

    
    Oncol Rep

44. LI X, Ma Y
    PINK1 promotes the progression of lung squamous cell carcinoma through the FAK/AKT/RhoA/vinculin pathway.
    Oncol Rep. 2026;56:195.
    PubMed         Abstract available
    
    
45. LAI H, Sun K, Mu T, Liu X, et al
    Mitochondrial mechanisms underlying spatial immune phenotypes in non?small cell lung cancer: Implications for ICI response and cold?to?hot tumor conversion (Review).
    Oncol Rep. 2026;56:196.
    PubMed         Abstract available
    
    

    
    Oncologist

46. SHEFFIELD BS, Baranova K, Cheema P, Bredella MA, et al
    Precision Oncology at Speed: Workflow Design Determines Clinical Utility in Rapid Molecular Testing for Lung Cancer.
    Oncologist. 2026 Oct 1:oyag388. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    PLoS One

47. ZUO X, Zhou Q, Pang L, Li G, et al
    Associations of dietary polyunsaturated fatty acids and sleep patterns with lung cancer in southwest China: A case-control study.
    PLoS One. 2026;21:e0358576.
    PubMed         Abstract available
    
    

    
    Science

48. HINTERLEITNER C, Barthet VJA, Goldberg HV, Vogt KC, et al
    Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer.
    Science. 2026;393:eaeg4791.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum